Entrar Registro gratuito

Hancock Jaffe Laboratories Inc EPS Est. T/T

Qual é o EPS Est. T/T de Hancock Jaffe Laboratories Inc?

O EPS Est. T/T de Hancock Jaffe Laboratories Inc é -72.00%

Qual é a definição de EPS Est. T/T?



A taxa de crescimento prospectiva trimestral do EPS, ano após ano , é o aumento estimado do EPS de uma empresa para o próximo trimestre em comparação com o desempenho do trimestre passado correspondente.

The prospective EPS growth rate is a predicted estimate of the earnings per share growth rate towards the current quarter and expressed as a percentage compared to the respective past quarter. The estimated earnings per share growth rate is an important factor for judging a company's value. Comparing EPS history with stock price history helps determine the most likely future direction of the stock price.

Earnings per share is the monetary value of earnings per outstanding share of common stock for a company. The EPS is usually calculated as profit without preferred dividends divided by weighted average of common stock shares over the past twelve months.

EPS Est. T/T de empresas na Setor Health Care em NASDAQ em comparação com Hancock Jaffe Laboratories Inc

O que Hancock Jaffe Laboratories Inc faz?

Hancock Jaffe Laboratories specializes in developing and manufacturing bioprosthetic (tissue-based) medical devices to establish improved standards of care for treating cardiac and vascular diseases. HJLI currently has two lead product candidates: the VenoValveÒ, a porcine-based valve which is intended to be surgically implanted in the deep venous system of the leg to treat reflux associated with Chronic Venous Insufficiency, and the CoreoGraftÒ, a bovine tissue-based off-the-shelf conduit intended to be used for coronary artery bypass surgery.

Empresas com eps est. t/t semelhantes a Hancock Jaffe Laboratories Inc